Not applicableStudy completedNCT01818947What this trial is testingGefitinib Usage and Outcomes in Routine TreatmentWho this might be right forLung Cancer AstraZeneca 157
Very early researchLooking for participantsNCT06824155What this trial is testingHEAT Trial (HER2 Antibody Therapy With Lutetium-177)Who this might be right forHER2 Gene MutationAdvanced Solid Tumors Radiopharm Theranostics, Ltd 30
Testing effectiveness (Phase 2)Ended earlyNCT02349633What this trial is testingStudy For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)Who this might be right forNon-Small Cell Lung Cancer Pfizer 65
Large-scale testing (Phase 3)Active Not RecruitingNCT04351555What this trial is testingOsimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerWho this might be right forNon-Small Cell Lung Cancer AstraZeneca 358
Large-scale testing (Phase 3)Active Not RecruitingNCT02511106What this trial is testingAZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.Who this might be right forStage IB-IIIA Non-small Cell Lung Carcinoma AstraZeneca 682
Testing effectiveness (Phase 2)Ended earlyNCT02495233What this trial is testingASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)Who this might be right forNon-Small-Cell Lung Cancer Astellas Pharma Global Development, Inc. 10
Large-scale testing (Phase 3)UnknownNCT04500704What this trial is testingAlmonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLCWho this might be right forNon Small Cell Lung Cancer Cancer Institute and Hospital, Chinese Academy of Medical Sciences 166
Large-scale testing (Phase 3)Study completedNCT01342965What this trial is testingErlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR MutationsWho this might be right forNon-Small Cell Lung Cancer Hoffmann-La Roche 217
Testing effectiveness (Phase 2)Looking for participantsNCT05498428What this trial is testingAmivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerWho this might be right forCarcinoma, Non-small-Cell Lung Janssen Research & Development, LLC 520
Not applicableStudy completedNCT03562819What this trial is testingStudy to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer).Who this might be right forNSCLC (Non-small Cell Lung Cancer) AstraZeneca 268
Not applicableLooking for participantsNCT06716580What this trial is testingEQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx PopulationsWho this might be right forLung CancerEGFR Gene Mutation Dana-Farber Cancer Institute 1,000
Early research (Phase 1)Active Not RecruitingNCT04676477What this trial is testingHER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung CancerWho this might be right forNon-Small Cell Lung Cancer (NSCLC) Daiichi Sankyo 246
Testing effectiveness (Phase 2)Active Not RecruitingNCT04285671What this trial is testingNecitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung CancerWho this might be right forMetastatic Lung Non-Small Cell CarcinomaRefractory Lung Non-Small Cell CarcinomaStage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8+2 more Jonsson Comprehensive Cancer Center
Large-scale testing (Phase 3)Study completedNCT03653546What this trial is testingFirst Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) MetastasesWho this might be right forNon-small Cell Lung CancerEGFR Gene MutationBrain Metastases Alpha Biopharma (Jiangsu) Co., Ltd. 492
Not applicableStudy completedNCT02475720What this trial is testingSurvey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC)Who this might be right forCarcinoma, Non-Small-Cell Lung AstraZeneca 2,000
Testing effectiveness (Phase 2)UnknownNCT04646824What this trial is testingAlmonertinib With Chemotherapy in mEGFR NSCLCWho this might be right forNon-Small Cell Lung Cancer Metastatic Tianjin Medical University Cancer Institute and Hospital 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT03330847What this trial is testingTo Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.Who this might be right forMetastatic Triple Negative Breast Cancer AstraZeneca 273
Early research (Phase 1)Study completedNCT00903734What this trial is testingAn Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation StatusWho this might be right forAdvanced Cancers M.D. Anderson Cancer Center 16
Testing effectiveness (Phase 2)Ended earlyNCT00503971What this trial is testingPhase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.Who this might be right forNon-small Cell Lung Cancer Spanish Lung Cancer Group 33
Not applicableStudy completedNCT03133234What this trial is testingEffect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLCWho this might be right forT790M Positive NSCLC Patients AstraZeneca 47